References
- Jadvar H. Ovarian cancer. PET-CT. 2005;327:579–581.
- Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19(1):3–10.
- Weberpals JI, Koti M, Squire JA. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genet. 2011;204(10):525–535.
- Weberpals JI, Koti M, Squire JA. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genet.2011;204(10):525–35.
- Akhade VS, Pal D, Kanduri C. Long noncoding RNA: genome organization and mechanism of action. Adv Exp Med Biol. 2017;1008:47–74.
- Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62.
- Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem. 2012;81:145–166.
- Alvarez-Dominguez JR, Lodish HF. Emerging mechanisms of long noncoding RNA function during normal and malignant hematopoiesis. Blood. 2017;130(18):1965–1975.
- Schmitz SU, Grote P, Herrmann BG. Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 2016;73(13):2491–2509.
- Kondo Y, Shinjo K, Katsushima K. Long non-coding RNAs as an epigenetic regulator in human cancers. Cancer Sci. 2017;108(10):1927–1933.
- Chi Y, Wang D, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8:1015.
- Xue M, Shi D, Xu G, et al. The long noncoding RNA linc00858 promotes progress of lung cancer through miR-3182/MMP2 axis. Artif Cells Nanomed Biotechnol. 2019;47(1):2091–2097.
- Sha QK, Chen L, Xi JZ, et al. Long non-coding RNA LINC00858 promotes cells proliferation, migration and invasion by acting as a ceRNA of miR-22-3p in colorectal cancer. Artif Cells Nanomed Biotechnol. 2019;47(1):1057–1066.
- Gu Z, Hou Z, Zheng L, et al. Long noncoding RNA LINC00858 promotes osteosarcoma through regulating miR-139-CDK14 axis. Biochem Biophys Res Commun. 2018;503(2):1134–1140.
- Liu S, Yin H, Ji H, et al. Overexpression of TRIM44 is an independent marker for predicting poor prognosis in epithelial ovarian cancer. Exp Ther Med. 2018;16:3034–3040.
- Fu LL, Li CJ, Xu Y, et al. Role of lncRNAs as novel biomarkers and therapeutic targets in ovarian cancer. Crit Rev Eukaryot Gene Expr. 2017;27(2):183–195.
- Tripathi MK, Doxtater K, Keramatnia F, et al. Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes. Drug Discov Today. 2018;23(9):1635–1643.
- Jin Y, Feng SJ, Qiu S, et al. LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway. Eur Rev Med Pharmacol Sci. 2017;21(14):3176–3184.
- Li R, Wang Y, Xu Y, et al. Silencing the long noncoding RNA, TINCR, a molecular sponge of miR335, inhibits the malignant phenotype of epithelial ovarian cancer via FGF2 suppression. Int J Oncol. 2019;55:1110–1124.
- Yan J, Jia Y, Chen H, et al. Long non-coding RNA PXN-AS1 suppresses pancreatic cancer progression by acting as a competing endogenous RNA of miR-3064 to upregulate PIP4K2B expression. J Exp Clin Cancer Res. 2019;38(1):390.
- Qin Q, Wei F, Zhang J, et al. miR-134 suppresses the migration and invasion of non‑small cell lung cancer by targeting ITGB1. Oncol Rep. 2017;37(2):823–830.
- Wang WW, Zhao ZH, Wang L, et al. MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway. EBioMedicine. 2019;46:66–78.
- Chang C, Liu T, Huang Y, et al. MicroRNA-134-3p is a novel potential inhibitor of human ovarian cancer stem cells by targeting RAB27A. Gene. 2017;605:99–107.
- Pan JY, Zhang F, Sun CC, et al. miR-134: a human cancer suppressor? Mol Ther Nucleic Acids. 2017;6:140–149.
- Liu B, Li J, Cairns MJ. Identifying miRNAs, targets and functions. Brief Bioinform. 2014;15(1):1–19.
- Peter ME. Targeting of mRNAs by multiple miRNAs: the next step. Oncogene. 2010;29(15):2161–2164.
- Tan Y, Yao H, Hu J, et al. Knockdown of TRIM44 inhibits the proliferation and invasion in prostate cancer cells. Oncol Res. 2017;25(8):1253–1259.
- Xing Y, Meng Q, Chen X, et al. TRIM44 promotes proliferation and metastasis in non‑small cell lung cancer via mTOR signaling pathway. Oncotarget. 2016;7(21):30479–30491.
- Liu S, Meng F, Ding J, et al. High TRIM44 expression as a valuable biomarker for diagnosis and prognosis in cervical cancer. Biosci Rep. 2019;39:BSR20181639.
- Xiong D, Jin C, Ye X, et al. TRIM44 promotes human esophageal cancer progression via the AKT/mTOR pathway. Cancer Sci. 2018;109(10):3080–3092.